PF 543 Chemical Properties

Boiling point:

666.0±55.0 °C(Predicted)

Density 

1.224±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

≥23.3 mg/mL in DMSO; insoluble in H2O; ≥51 mg/mL in EtOH with gentle warming and ultrasonic

pka

14.77±0.10(Predicted)

form 

powder

color 

white to light brown

PF 543 Usage And Synthesis

Definition

ChEBI: [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol is a sulfonamide.

General Description

A cell-permeable hydroxymethylpyrrolidine compound that acts as a high affinity (K_d = 5 nM, k_offt_1/2 = 8.5 min), but poor, sphingosine kinase-1/SphK1 substrate (1/1,500 of sphingosine processivity) and potently inhibits against SphK1-catalyzed sphingosine-to-S1P conversion (IC₅₀ = 2.0 nM; [sphingosine] = 3 μM) in a reversible, sphingosine-, but not ATP-, competitive manner (K_i = 3.6 nM), exhibiting 132-fold selectivity over SphK2, no affinity toward S1P receptors (S1P1, S1P2, S1P3, S1P5), and much reduced or no inhibitory activity against a panel of 46 other lipid and protein kinases (IC₅₀ >10 μM), including the structurally related diacylglyerol kinase α/DAGKα (3.7% inhibition at 10 μM). PF-543 exposure in 1483 squamous cultures is reported to result in intracellular S1P depletion (by 90% upon 1 h 200 nM or 7 d 1 μM drug exposure) with concomitant elevation of sphingosine level and no detectable cytotoxicity (1 μM for 7 to 9 d in 1483, A549, Jurkat, LN229, MCF7, or U937 cultures). Also active in human whole blood assays in the presence human & bovine serum proteins (IC₅₀ = 26.7 nM against cellular C₁₇-S1P formation from exogenously added 20 μM C₁₇-sphingosine in 10 min with 30 min drug preincubation).

Biological Activity

pf-543 is a novel and cell-permeant inhibitor of sphingosine kinase (sphk1) with ic50 value of 3.6 nm [1],sphk1 is a kinase that phosphorylates sphingosine to sphingosine-1-phosphate (sip). sphk1 is normally a cytosolic protein but can be recruited to the membrane to conduct its activity. it is the major source of production of s1p which promotes cell growth, survival and migration, and also regulate lymphocyte trafficking.biochemical study has identified that sphk1 was a sphingosine-competitive inhibitor but not atp-competitive [1]. in 1483 head and neck carcinoma cell cultures expressing high levels of sphk1 and with an unusually high rate of s1p production, pretreatment of pf-543 for 1 hr decreased the level of endogenous s1p by 10-fold with a proportional increase in the level of sphingosine. it indicated a significant inhibition of sphk1 by pf-543. however, specific inhibition of sphk1 had no effect on the proliferation and survival of 1483 cell cultures, despite a dramatic change in the cellular s1p/sphingosine rate [1].the inhibitory activity of pf-543 was also examined ex vivo in human whole blood. human whole blood with high sphk1 activity was prepared, which was able to quickly convert c17-sphingosine to c17-s1p. pf-543 treatment showed that pf-543 was a potent inhibitor of sphk1, capable of blocking >90% c17-s1p formation [1].

Biochem/physiol Actions

PF-543 hydrochloride is a novel, cell-permeable, potent and selective inhibitor of sphingosine kinase-1 (SphK1). PF-543 inhibits SphK1 with a Ki of 3.6 nM, is sphingosine competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. PF-543 decreased the level of endogenous S1P by 10-fold with proportional increase of the level of sphingosine.

target

SphK1

References

[1] schnute m e et al. , modulation of cellular s1p levels with a novel, potent and specific inhibitor of sphingosine kinase-1. biochem j. 2012, 444(1): 79-88.

PF 543(1415562-82-1)Related Product Information

• PF-06281355
• PF-562271
• Ketohexokinase inhibitor 1
• PF-6274484
• PF-9366
• 4-[(Diethylamino)methyl]-N-[2-(2-methoxyphenyl)ethyl]-N-(3R)-3-pyrrolidinylbenzamide
• 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione
• PF06869206
• PF06869206
• Valspodar
• ALK5 inhibitor II
• PF-543 (Citrate)
• CHIR-99021
• MK-2206 2HCl
• ABT 737
• NSC 23766 (hydrochloride)
• ABT 263
• Thalidomide